Clear + Brilliant Before and After: What Results Look Like

The starting point is the clearance, because it is narrower than a gallery implies.

Clear + Brilliant Touch is 510(k)-cleared — cleared, not FDA-approved — for "dermatological procedures requiring the coagulation of soft tissue and general skin resurfacing procedures" (K223647, cleared December 29, 2022).

No skin condition is named in that wording.

The device has been cleared since 2011: the original 1440 nm system was cleared May 3, 2011 (K110349), and a 1927 nm handpiece, marketed as Perméa, was added in 2012 (K120433).

The current Touch system carries both handpieces.

What the maker says you can expect is about how skin feels and looks rather than any named condition: Solta says skin starts to feel softer and look brighter within a week or two after one treatment, and that results "can last for months" depending on age, skin condition and how you protect your skin.

The published evidence nearest this device sits at the level of the laser class.

A 2020 review of 1440/1927 nm non-ablative fractional diode lasers — the class that includes Solta's Clear + Brilliant-type system — reports improvements in tone, texture, fine lines and dyschromia (uneven pigment), with transient side effects and minimal downtime.

It is class evidence, published as a journal supplement — likely an industry-supported one — not a Clear + Brilliant trial.

The Clear + Brilliant guide covers the device, candidacy and cost; this page stays on what changes in the skin, session by session and concern by concern.

Solta's series comes from consumer self-reports: in studies the company cites, consumers reported visible improvement after 4–6 treatments.

The measure behind it is the maker reporting what consumers said — not a scored trial endpoint our sources describe — and 4–6 is the only session count our sources carry for this device.

The maker also describes a one-treatment effect: skin feeling softer and looking brighter within a week or two.

Both can sit together in Solta's telling — an early change after one session, visible improvement reported after a series of 4–6 — but no study we found measures what each additional session adds.

That makes "after 6 treatments" a question to ask a practice rather than a milestone the record defines.

Six is the top of the maker's own range, and Solta says many continue routine treatments as part of their overall skincare regimen afterward.

Whether a sixth session changes anything visible for your skin is a licensed provider's judgment, not something a source on this page can settle.

Here is the concern-by-concern record, with each row kept to what its source actually says, and for which device.

The melasma row deserves its own numbers.

A 2020 evidence-based review of 113 studies and 6,897 participants concluded hydroquinone and triple-combination cream are the most effective, best-studied melasma treatments, and put chemical peels and laser or light therapies at "equal or inferior to topicals" with a higher risk of adverse effects.

If melasma is the concern behind your search, those topicals are the best-studied treatments in the evidence we carry — a conversation for a dermatologist — and any laser role in it is a question for that clinician.

The maker names three variables in its own duration wording: age, skin condition and sun protection.

Those are Solta's factors for how results "can last for months" — and the only result-length variables any source on this page gives.

Session count is the other lever the record names, and it is a self-reported one.

What the record lacks matters just as much: we found no Clear + Brilliant study comparing ages, skin types or device settings, and no figure for how results differ between the 1440 nm and 1927 nm handpieces.

Those are consultation questions, not lookup facts.

Timing changes what a photo can show, too.

The maker lists mild-to-moderate redness and swelling right after treatment that usually diminishes or resolves within 12 to 24 hours, plus itching or dryness, skin sensitivity, discomfort and rarely pinpoint bleeding.

A photo taken the same day mostly shows those short-term effects, not the settled result — which is why the time point on any photo matters.

Candidacy is the last variable, and it is the maker's own list: retinoid use within the past 2 weeks, isotretinoin, or Botox or filler within the past 2 weeks, alongside melasma, rosacea, actinic keratosis and the other flags in its safety information.

Anything on that list changes the conversation before it changes the outcome.

Photos in a practice's marketing are advertising first.

Under the FTC Endorsement Guides (16 CFR 255.2), a result shown in an ad is read as representative of what consumers will generally achieve; if the advertiser cannot substantiate that, the ad must clearly and conspicuously disclose the generally expected results, and the FTC says disclaimers like "Results not typical" are generally insufficient on their own.

Manufacturer galleries model the labeling worth looking for: photos often carry the treatment count and the time point, alongside captions like "Unretouched photos. Actual patient. Individual results may vary." Treatment count, time since treatment, lighting and whether photos are unretouched are the four things to check before any gallery means anything.

Photos are also patient data.

Under HIPAA, full-face photographs and comparable images are among the identifiers that keep health information from counting as de-identified (45 CFR 164.514(b)(2)(i)(Q)), and before-and-after photos taken by a covered provider are protected health information — a HIPAA covered entity needs the patient's written authorization before using them in marketing (45 CFR 164.508(a)(3)).

Whether a given med spa counts as a HIPAA covered entity depends on factors such as whether it bills insurance electronically — so it is fair to ask how a photo you are shown was cleared for use.

One last frame for the whole page: a gallery is evidence about a practice's patients, not a forecast for yours.

The questions above turn it into something usable — and a practice that cannot answer them has answered a different question.